标题
Targeting the mTOR Pathway in Leukemia
作者
关键词
-
出版物
JOURNAL OF CELLULAR BIOCHEMISTRY
Volume 117, Issue 8, Pages 1745-1752
出版商
Wiley
发表日期
2016-03-28
DOI
10.1002/jcb.25559
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Targeting NOTCH1 in T-ALL: Starving the dragon
- (2016) Daniel Herranz et al. CELL CYCLE
- The PI3K/mTOR inhibitor PF-04691502 induces apoptosis and inhibits microenvironmental signaling in CLL and the E -TCL1 mouse model
- (2015) M. D. Blunt et al. BLOOD
- Targeting mTOR signaling pathways and related negative feedback loops for the treatment of acute myeloid leukemia
- (2015) Benedito A Carneiro et al. CANCER BIOLOGY & THERAPY
- Rapamycin restores p14, p15 and p57 expression and inhibits the mTOR/p70S6K pathway in acute lymphoblastic leukemia cells
- (2015) Huibo Li et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies
- (2015) G S Choudhary et al. Cell Death & Disease
- Dual targeting of acute myeloid leukemia progenitors by catalytic mTOR inhibition and blockade of the p110α subunit of PI3 kinase
- (2015) Marco Colamonici et al. Oncotarget
- Triple Akt inhibition as a new therapeutic strategy in T-cell acute lymphoblastic leukemia
- (2015) Alice Cani et al. Oncotarget
- The pan-class I phosphatidyl-inositol-3 kinase inhibitor NVP-BKM120 demonstrates anti-leukemic activity in acute myeloid leukemia
- (2015) Matteo Allegretti et al. Scientific Reports
- FAK Mediates a Compensatory Survival Signal Parallel to PI3K-AKT in PTEN-Null T-ALL Cells
- (2015) Dewen You et al. Cell Reports
- Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia
- (2015) Kathryn G. Roberts et al. NEW ENGLAND JOURNAL OF MEDICINE
- A combination of temsirolimus, an allosteric mTOR inhibitor, with clofarabine as a new therapeutic option for patients with acute myeloid leukemia
- (2015) Francesca Chiarini et al. Oncotarget
- A potential therapeutic strategy for chronic lymphocytic leukemia by combining Idelalisib and GS-9973, a novel spleen tyrosine kinase (Syk) inhibitor
- (2015) Russell T Burke et al. Oncotarget
- mTOR kinase inhibitors synergize with histone deacetylase inhibitors to kill B-cell acute lymphoblastic leukemia cells
- (2015) Brandon R. Beagle et al. Oncotarget
- IPI-145 antagonizes intrinsic and extrinsic survival signals in chronic lymphocytic leukemia cells
- (2014) S. Dong et al. BLOOD
- Autophagy Is a Survival Mechanism of Acute Myelogenous Leukemia Precursors during Dual mTORC2/mTORC1 Targeting
- (2014) J. K. Altman et al. CLINICAL CANCER RESEARCH
- Dual PI3K/mTOR inhibition shows antileukemic activity in MLL-rearranged acute myeloid leukemia
- (2014) N Sandhöfer et al. LEUKEMIA
- Disruption of autophagy by the histone deacetylase inhibitor MGCD0103 and its therapeutic implication in B-cell chronic lymphocytic leukemia
- (2014) V El-Khoury et al. LEUKEMIA
- Evaluation of Apoptosis Induction by Concomitant Inhibition of MEK, mTOR, and Bcl-2 in Human Acute Myelogenous Leukemia Cells
- (2014) W. Zhang et al. MOLECULAR CANCER THERAPEUTICS
- Loss of mTOR complex 1 induces developmental blockage in early T-lymphopoiesis and eradicates T-cell acute lymphoblastic leukemia cells
- (2014) T. Hoshii et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- A therapeutically targetable mechanism of BCR-ABL-independent imatinib resistance in chronic myeloid leukemia
- (2014) L. Ma et al. Science Translational Medicine
- Akt inhibitor MK2206 selectively targets CLL B-cell receptor induced cytokines, mobilizes lymphocytes and synergizes with bendamustine to induce CLL apoptosis
- (2013) Wei Ding et al. BRITISH JOURNAL OF HAEMATOLOGY
- Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with nilotinib against BCR-ABL-positive leukemia cells involves the ABL kinase domain mutation
- (2013) Seiichi Okabe et al. CANCER BIOLOGY & THERAPY
- Mechanistic / mammalian target protein of rapamycin signaling in hematopoietic stem cells and leukemia
- (2013) Atsushi Hirao et al. CANCER SCIENCE
- Mammalian target of rapamycin inhibitor rapamycin enhances anti-leukemia effect of imatinib on Ph+acute lymphoblastic leukemia cells
- (2013) Xi Yang et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Diverse mechanisms of mTOR activation in chronic and blastic phase of chronic myelogenous leukemia
- (2013) Tomasz Stoklosa et al. EXPERIMENTAL HEMATOLOGY
- Targeting phosphatidylinositol 3-kinase signaling in acute myelogenous leukemia
- (2013) Camilla Evangelisti et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Toward a NOTCH1/FBXW7/RAS/PTEN–Based Oncogenetic Risk Classification of Adult T-Cell Acute Lymphoblastic Leukemia: A Group for Research in Adult Acute Lymphoblastic Leukemia Study
- (2013) Amélie Trinquand et al. JOURNAL OF CLINICAL ONCOLOGY
- Combined inhibition of the phosphoinosityl-3-kinase (PI3Kinase) P110δ subunit and mitogen-extracellular activated protein kinase (MEKinase) shows synergistic cytotoxicity against human acute myeloid leukemia progenitors
- (2013) Yan Xing et al. LEUKEMIA RESEARCH
- Regulatory Effects of Sestrin 3 (SESN3) in BCR-ABL Expressing Cells
- (2013) Eliza Vakana et al. PLoS One
- Inhibition of PI3K/mTOR Overcomes Nilotinib Resistance in BCR-ABL1 Positive Leukemia Cells through Translational Down-Regulation of MDM2
- (2013) Jie Ding et al. PLoS One
- The microenvironment in chronic lymphocytic leukemia (CLL) and other B cell malignancies: Insight into disease biology and new targeted therapies
- (2013) Jan A. Burger et al. SEMINARS IN CANCER BIOLOGY
- PI3K/mTOR pathway inhibitors sensitize chronic myeloid leukemia stem cells to nilotinib and restore the response of progenitors to nilotinib in the presence of stem cell factor
- (2013) K Airiau et al. Cell Death & Disease
- Aberrant STAT5 and PI3K/mTOR pathway signaling occurs in human CRLF2-rearranged B-precursor acute lymphoblastic leukemia
- (2012) S. K. Tasian et al. BLOOD
- Targeting of mTORC1/2 by the mTOR kinase inhibitor PP242 induces apoptosis in AML cells under conditions mimicking the bone marrow microenvironment
- (2012) Z. Zeng et al. BLOOD
- Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia
- (2012) S. L. Maude et al. BLOOD
- An overview of the mTOR pathway as a target in cancer therapy
- (2012) Ryan D Gentzler et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Therapeutic potential of MEK inhibition in acute myelogenous leukemia: rationale for “vertical” and “lateral” combination strategies
- (2012) Maria Rosaria Ricciardi et al. JOURNAL OF MOLECULAR MEDICINE-JMM
- The evolution of the TOR pathway and its role in cancer
- (2012) E M Beauchamp et al. ONCOGENE
- The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia
- (2011) J. Hoellenriegel et al. BLOOD
- Temsirolimus, an mTOR inhibitor, in combination with lower-dose clofarabine as salvage therapy for older patients with acute myeloid leukaemia: results of a phase II GIMEMA study (AML-1107)
- (2011) Sergio Amadori et al. BRITISH JOURNAL OF HAEMATOLOGY
- Activation of mTORC2 by Association with the Ribosome
- (2011) Vittoria Zinzalla et al. CELL
- Dual mTORC2/mTORC1 Targeting Results in Potent Suppressive Effects on Acute Myeloid Leukemia (AML) Progenitors
- (2011) J. K. Altman et al. CLINICAL CANCER RESEARCH
- High-level IGF1R expression is required for leukemia-initiating cell activity in T-ALL and is supported by Notch signaling
- (2011) Hind Medyouf et al. JOURNAL OF EXPERIMENTAL MEDICINE
- BCR-ABL1-independent PI3Kinase activation causing imatinib-resistance
- (2011) Hilmar Quentmeier et al. Journal of Hematology & Oncology
- Regulation of mammalian target of rapamycin and mitogen activated protein kinase pathways by BCR–ABL
- (2011) Amanda J. Redig et al. LEUKEMIA & LYMPHOMA
- Selective targeting of the mTORC1/2 protein kinase complexes leads to antileukemic effects in vitro and in vivo
- (2011) K Schuster et al. Blood Cancer Journal
- Induction of autophagy by dual mTORC1-mTORC2 inhibition in BCR-ABL-expressing leukemic cells
- (2010) Eliza Vakana et al. Autophagy
- CAL-101, a p110 selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability
- (2010) B. J. Lannutti et al. BLOOD
- Dual Inhibition of PI3K and mTORC1/2 Signaling by NVP-BEZ235 as a New Therapeutic Strategy for Acute Myeloid Leukemia
- (2010) N. Chapuis et al. CLINICAL CANCER RESEARCH
- mTOR: from growth signal integration to cancer, diabetes and ageing
- (2010) Roberto Zoncu et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Critical roles for mTORC2- and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells
- (2010) Nathalie Carayol et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia
- (2009) A. Gutierrez et al. BLOOD
- A Phase I Study of the Mammalian Target of Rapamycin Inhibitor Sirolimus and MEC Chemotherapy in Relapsed and Refractory Acute Myelogenous Leukemia
- (2009) A. E. Perl et al. CLINICAL CANCER RESEARCH
- Akt is activated in chronic lymphocytic leukemia cells and delivers a pro-survival signal: the therapeutic potential of Akt inhibition
- (2009) J. Zhuang et al. HAEMATOLOGICA
- CSL–MAML-dependent Notch1 signaling controls T lineage–specific IL-7Rα gene expression in early human thymopoiesis and leukemia
- (2009) Sara González-García et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Rapamycin and curcumin induce apoptosis in primary resting B chronic lymphocytic leukemia cells
- (2009) Rami Hayun et al. LEUKEMIA & LYMPHOMA
- Deletion ofIKZF1and Prognosis in Acute Lymphoblastic Leukemia
- (2009) Charles G. Mullighan et al. NEW ENGLAND JOURNAL OF MEDICINE
- mTOR inhibitors are synergistic with methotrexate: an effective combination to treat acute lymphoblastic leukemia
- (2008) D. T. Teachey et al. BLOOD
- A Phase 2 Clinical Trial of Deforolimus (AP23573, MK-8669), a Novel Mammalian Target of Rapamycin Inhibitor, in Patients with Relapsed or Refractory Hematologic Malignancies
- (2008) D. A. Rizzieri et al. CLINICAL CANCER RESEARCH
- PTEN posttranslational inactivation and hyperactivation of the PI3K/Akt pathway sustain primary T cell leukemia viability
- (2008) Ana Silva et al. JOURNAL OF CLINICAL INVESTIGATION
- Lack of antileukemic activity of rapamycin in elderly patients with acute myeloid leukemia evolving from a myelodysplastic syndrome
- (2008) Fernando Callera et al. LEUKEMIA RESEARCH
- Hypersensitivity of Ph-positive lymphoid cell lines to rapamycin: Possible clinical application of mTOR inhibitor
- (2008) Chikara Hirase et al. LEUKEMIA RESEARCH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started